Sagimet Biosciences Inc (SGMT)

Oct 10, 2025

Sagimet Biosciences Inc. stock retracement – recovery analysisEarnings Risk Report & Verified Trade Idea Suggestions - newser.com

Oct 10, 2025

Oct 10, 2025

Is a relief rally coming for Sagimet Biosciences Inc. holdersJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com

Oct 10, 2025

Oct 10, 2025

Is Sagimet Biosciences Inc. forming a reversal pattern2025 Momentum Check & Consistent Profit Trading Strategies - newser.com

Oct 10, 2025

Oct 10, 2025

Using flow based indicators on Sagimet Biosciences Inc.July 2025 Decliners & Capital Efficient Trade Techniques - newser.com

Oct 10, 2025

Oct 10, 2025

Has Sagimet Biosciences Inc. found a price floorAnalyst Upgrade & Stock Market Timing Techniques - newser.com

Oct 10, 2025

Oct 10, 2025

Developing predictive dashboards with Sagimet Biosciences Inc. dataWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Will Sagimet Biosciences Inc. (0O2) stock justify high valuationWeekly Investment Recap & Risk Controlled Daily Trade Plans - newser.com

Oct 10, 2025

Oct 09, 2025

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN

Oct 09, 2025

Oct 09, 2025

Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha

Oct 09, 2025

Oct 09, 2025

Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 09, 2025

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 09, 2025

Oct 09, 2025

Will Sagimet Biosciences Inc. benefit from macro trends2025 Key Lessons & Smart Money Movement Tracker - newser.com

Oct 09, 2025

Oct 07, 2025

Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha

Oct 07, 2025

Oct 07, 2025

Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative

Oct 07, 2025

Oct 07, 2025

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire

Oct 07, 2025

Oct 07, 2025

≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan

Oct 07, 2025

Oct 06, 2025

Using Ichimoku Cloud for Sagimet Biosciences Inc. technicalsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com

Oct 06, 2025

Oct 06, 2025

Why analysts recommend Sagimet Biosciences Inc. (0O2) stock2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com

Oct 06, 2025

Oct 05, 2025

Using data tools to time your Sagimet Biosciences Inc. exit2025 Risk Factors & Daily Stock Trend Watchlist - newser.com

Oct 05, 2025

Oct 05, 2025

Is Sagimet Biosciences Inc. stock ready for a breakoutJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com

Oct 05, 2025

Oct 03, 2025

Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at Canaccord Genuity Group - Defense World

Oct 03, 2025

Oct 03, 2025

Risk vs reward if holding onto Sagimet Biosciences Inc.Trade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com

Oct 03, 2025

Oct 03, 2025

Has Sagimet Biosciences Inc. formed a bullish divergenceExit Point & Safe Entry Trade Signal Reports - newser.com

Oct 03, 2025

Oct 03, 2025

Applying big data sentiment scoring on Sagimet Biosciences Inc.Gap Down & Weekly Market Pulse Alerts - newser.com

Oct 03, 2025

Oct 02, 2025

Canaccord Genuity Maintains Sagimet Biosciences (SGMT) Buy Recommendation - Nasdaq

Oct 02, 2025

Oct 02, 2025

Canaccord Genuity Group Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat

Oct 02, 2025

Oct 02, 2025

Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential - TipRanks

Oct 02, 2025

Oct 02, 2025

Goldman Sachs Group Inc. Sells 109,464 Shares of Sagimet Biosciences Inc. $SGMT - Defense World

Oct 02, 2025

Oct 01, 2025

Sagimet Biosciences Inc Stock Analysis and ForecastInsider Selling Patterns & Minimal Investment Portfolio Growth - earlytimes.in

Oct 01, 2025

Oct 01, 2025

Published on: 2025-10-01 08:26:59 - newser.com

Oct 01, 2025

Oct 01, 2025

Sagimet Biosciences Inc. Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - MarketScreener

Oct 01, 2025

Oct 01, 2025

Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom - TipRanks

Oct 01, 2025

Oct 01, 2025

Sagimet Biosciences Initiates Phase 1 Trial for Combination Therapy Targeting Metabolic Dysfunction-Associated Steatohepatitis - Quiver Quantitative

Oct 01, 2025

Oct 01, 2025

Sagimet Biosciences Announces Dosing of First Participants - GlobeNewswire

Oct 01, 2025

Oct 01, 2025

Novel MASH Drug Combination: Sagimet Launches Phase 1 Trial for Denifanstat-Resmetirom Treatment - Stock Titan

Oct 01, 2025

Oct 01, 2025

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - Sahm

Oct 01, 2025

Oct 01, 2025

Kranti Industries Limited (542459) Expands into New MarketSupport Level Holds & Low Entry Cost Investment - earlytimes.in

Oct 01, 2025

Sep 30, 2025

Is Sagimet Biosciences Inc a good long term investmentStock Liquidity Analysis & Outstanding Growth Portfolio - earlytimes.in

Sep 30, 2025

Sep 29, 2025

What Price to Sales Ratio Tells Us About Tridhya Tech LimitedDebt-to-Equity Ratio Analysis & Low Risk Trading Ideas - earlytimes.in

Sep 29, 2025